Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DLBCL Interim Response Evaluation for Customised Therapy

NCT04226937 is registered in ClinicalTrials.gov with Cambridge University Hospitals NHS Foundation Trust as lead sponsor.

NCT NCT04226937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04226937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DLBCL Interim Response Evaluation for Customised Therapy
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust
Phase
Observational
Overall status
Unknown status
Start date
September 17, 2020
Completion date
September 1, 2025
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade b-cell lymphoma